
Supplementary Figures

HITIMED: Hierarchical Tumor Immune Microenvironment Epigenetic Deconvolution for accurate cell type resolution in the tumor microenvironment using tumor-type-specific DNA methylation data


Table of Contents

Supplementary Figure 1. Correlation between HiTIMED tumor and InfiniumPurify tumor by tumor type across cholangiocarcinoma, kidney papillary cell carcinoma, pancreatic adenocarcinoma, and stomach adenocarcinoma	3
Supplementary Figure 2. Methylation state of CpGs in the HiTIMED tumor specific library (L1) and InfiniumPurify default library	ļ
Supplementary Figure 3. HiTIMED tumor purity vs InfiniumPurify tumor purity in thyroid carcinoma	5
Supplementary Figure 4. HiTIMED tumor proportion vs other method predicted tumor proportion	5
Supplementary Figure 5. HiTIMED immune cell proportions vs true immune cell proportions in artificial mixtures	1
Supplementary Figure 6. HiTIMED T cell proportion vs true T cell proportion in artificial mixtures	3
Supplementary Figure 7. HiTIMED cell composition in human normal intestinal epithelium and umbilical vein endothelial cells)
Supplementary Figure 8. Performance comparison across HiTIMED, MethylCIBERSORT, and MethylResolver using artificial mixtures)
Supplementary Figure 9. The distribution of the HiTIMED cell composition in TCGA tumors	L
Supplementary Figure 10. Cell composition differs substantially and captures sample heterogeneity using <i>HiTIMED</i> -projected proportions. Seventeen cell types were captured for each sample by tumor type	2
Supplementary Figure 11. Sensitive analysis comparing outputs from two Cox models with or without cell type proportions adjusted in kidney clear cell carcinoma	3
Supplementary Figure 12. Kaplan-Meier survival curves for HiTIMED cells estimates in TCGA tumors	1
Supplementary Figure 13. HiTIMED cell comparison and Kaplan-Meier survival curves across immune/angiogenic hot and cold	5
Supplementary Figure 14. HiTIMED immune and angiogenic proportions across C1-C6 subtyped TCGA tumor	ŝ


Supplementary Figure 15. HiTIMED cell comparisons between drug-sensitive and -resistant metastasized colorectal cancer
Supplementary Figure 16. HiTIMED cell comparisons in triple-negative breast cancer w/without chemotherapy
Supplementary Figure 17. Performance comparison across iterations on CpGs selected in HiTIMED for immune and angiogenic cell projection. 19




Supplementary Figure 1. Correlation between *HiTIMED* tumor and *InfiniumPurify* tumor by tumor type. *HiTIMED* projected tumor proportions are highly significantly correlated with the *InfiniumPurify* predicted tumor purities across tumor types.




Supplementary Figure 2. Methylation state of CpGs in the *HiTIMED* tumor specific library (L1) and *InfiniumPurify* default library between tumor and normal samples across cholangiocarcinoma, kidney papillary cell carcinoma, pancreatic adenocarcinoma, and stomach adenocarcinoma.




Supplementary Figure 3. *HiTIMED* tumor purity vs *InfiniumPurify* tumor purity in thyroid carcinoma. **Panel A.** A cluster of *HiTIMED*-predicted tumor purity low but *InfiniumPurify*-predicted high tumor was identified and colored in heatmaps. **Panel B.** *HiTIMED* tumor proportion in thyroid carcinoma colored by invasive and non-invasive tumor type.



Supplementary Figure 4. *HiTIMED* tumor proportion vs other method predicted tumor proportion.




Supplementary Figure 5. HiTIMED immune cell proportions vs true immune cell proportions in artificial mixtures.




Supplementary Figure 6. *HiTIMED* T cell proportion vs true T cell proportion in artificial mixtures.


Note: T cell proportions correspond to the sum of CD4T naive and memory, CD8 naive and memory and T regulatory cells.




Supplementary Figure 7. *HiTIMED* cell composition in human normal intestinal epithelium and umbilical vein endothelial cells.



Supplementary Figure 8. Performance comparison across HiTIMED, MethylCIBERSORT, and MethylResolver using artificial mixtures.




Supplementary Figure 9. The distribution of the *HiTIMED* cell composition in TCGA tumors.




Supplementary Figure 10. Cell composition differs substantially and captures sample heterogeneity using *HiTIMED*-projected proportions. Seventeen cell types were captured for each sample by tumor type.

Kidney clear cell carcinoma




Cox model with age, gender, tumor stage, and HiTIMED-projected cell proportions adjusted




¹Cell types include tumor, Treg, CD8mem, Bmem, DC, stromal, epithelial, endothelial


Supplementary Figure 11. Sensitive analysis comparing outputs from two Cox models with or without cell type proportions adjusted in kidney clear cell carcinoma.




Supplementary Figure 12. Kaplan-Meier survival curves for *HiTIMED* cells estimates in TCGA tumors. Hazard ratios were calculated from the Cox proportional hazard models with age, gender, and tumor proportion adjusted (gender was not adjusted for gender-specific tumors).



Supplementary Figure 13. Panel A. *HiTIMED* cell comparison and Panel B. Kaplan-Meier survival curves across immune/angiogenic hot and cold tumors. P-values were calculated from the log-rank tests.




Supplementary Figure 14. *HiTIMED* immune and angiogenic proportions across C1-C6 subtyped TCGA tumor.




Group 🖨 drug-sensitive mCRC 🖨 first-line primary-resistant mCRC

Supplementary Figure 15. *HiTIMED* cell comparisons between drug-sensitive and -resistant metastasized colorectal cancer.



Supplementary Figure 16. *HiTIMED* cell comparisons in triple–negative breast cancer w/without chemotherapy.



Supplementary Figure 17. Performance comparison across iterations on CpGs selected in *HiTIMED* for immune and angiogenic cell projection.